6\tNot reached\t \t\t \tM308\tBRAFV600E Heterozygous\t3\tMITF amplificationAKT2 amplificationEGFR amplificationCDKN2A heterozygous deletion\t35.0\tNot reached\t \t\t \tM263\tBRAFV600E Heterozygous\t2\tCDKN2A heterozygous deletion\t23.3\t10\t \t\t \tM321\tBRAFV600E Homozygous\t2\t\t34.1\t7.5\t \t\t \tSKMEL28\tBRAFV600E Homozygous\t2\tEGFR P753SMITF amplificationCCND1 amplificationCDKN2A heterozygous deletionPTEN heterozygous deletion\t26.9\t4.6\t \t\t \tM229\tBRAFV600E Homozygous\t4\tMITF amplificationAKT1 amplificationPTEN heterozygous deletion\t27.9\t0.2\t \t\t \tM238\tBRAFV600E Heterozygous\t2\tCDKN2A homozygous deletionPTEN heterozygous deletion\t28.1\t0.7\t \t\t \tM249\tBRAFV600E Heterozygous\t3\tMITF amplificationAKT2 amplificationPTEN homozygous deletion\t21.2\t0.8\t \t\t \tM262\tBRAFV600E Homozygous\t2\tAKT1 E17KAKT1 amplificationEGFR amplificationCDKN2A homozygous deletion\t47.4\t0.1\t \t", "sentences": [], "annotations": [], "relations": []}, {"offset": 12798, "infons": {"file": "1479-5876-8-39-1.jpg", "id": "F1", "section_type": "FIG", "type": "fig_caption"}, "text": "PLX4032 modulation of the MAPK pathway and melanoma cell line viability. Melanoma cell lines treated with 1 muM PLX4032 for 20 hours were stained with pErk antibody and analyzed by flow cytometry. a) Representative flow cytometry histogram showing the fluorescence intensity of pErk in cells treated with vehicle control or PLX4032. b) Comparison of percentage change in pErk for a panel of 10 melanoma cell lines with different NRAS/BRAF mutational status. c) In vitro cell viability upon culture with increasing concentrations of PLX4032 (from 0.001-10 muM) for 120 hours. Cell viability was determined using an MTS-based assay.", "sentences": [], "annotations": [], "relations": []}, {"offset": 13429, "infons": {"section_type": "RESULTS", "type": "title_2"}, "text": "Differential sensitivity to PLX4032 in BRAFV600E mutated melanoma cell lines", "sentences": [], "annotations": [], "relations": []}, {"offset": 13506, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "Melanoma cell lines with different NRAS/BRAF mutational status were treated in vitro with a range of concentrations of PLX4032 for 5 days. The three cell lines without BRAFV600E mutation were resistant to PLX4032. Seven BRAFV600E mutant cell lines were sensitive to PLX4032, including four highly sensitive cell lines with half maximal inhibitory concentration (IC50) values below 1 muM. Surprisingly, in three cell lines with BRAFV600E mutation we could not determine an IC50 with increasing concentrations of PLX4032 up to 10 muM, suggesting that these cell lines are resistant to this agent in a 5-day exposure in vitro (Figure 1C). Similar results have been obtained in 3-day viability assays and when PLX4032 is added daily to the cultures or just at the beginning of the experiment (data not shown).", "sentences": [], "annotations": [], "relations": []}, {"offset": 14312, "infons": {"section_type": "RESULTS", "type": "title_2"}, "text": "PLX4032 has similar inhibitory effects on cell cycle in sensitive and resistant BRAFV600E mutant cell lines", "sentences": [], "annotations": [], "relations": []}, {"offset": 14420, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "To study effects of PLX4032 on cell cycle progression downstream of B-Raf signaling we used propidium iodide flow cytometric staining. As expected, PLX4032 had no effect on cell cycle progression in melanoma cell lines without a BRAFV600E mutation (Figure 2A). In contrast, PLX4032 exposure for one (data not shown) or 20 hours (Figure 2B and 2C) led to a similar and profound G1 arrest in all BRAFV600E mutant cell lines regardless of their in vitro sensitivity to PLX4032.", "sentences": [], "annotations": [], "relations": []}, {"offset": 14895, "infons": {"file": "1479-5876-8-39-2.jpg", "id": "F2", "section_type": "FIG", "type": "fig_caption"}, "text": "Effects of PLX4032 on cell cycle and apoptosis. a-c) Melanoma cell lines were cultured with 1 muM of PLX4032 for 20 hours and stained with propidium iodide for cell cycle analysis gated on live cells. a) NRAS Q61L mutants, b) BRAFV600E mutants resistant to PLX4032, c) BRAFV600E mutants sensitive to PLX4032. d-e) Melanoma cell lines were cultured with 1 muM of PLX4032, vehicle control, or 1 muM of staurosporine (SSP - positive control to induce apoptosis) for 120 hours and analyzed by flow cytometry for apoptotic cell death upon double-staining with Annexin V and propidium iodide. Testing included a PLX4032-resistant cell line (M233) and a highly sensitive cell line (M249), both of which are BRAFV600E mutants.